Supplementary Figure 4 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma | Synapse
July 17, 2024
Supplementary Figure 4 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
This figure shows the single cell RNA sequencing analysis of EGFR high tumor subcluster in the humanized LUSC PDX model.